Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial.
Porkaew PetchkumSomnuek SungkanuparphSasisopin KiertiburanakulAngsana PhuphuakratPublished in: Open forum infectious diseases (2019)
Switching from NVP to RPV can maintain virological suppression and decrease total cholesterol and triglyceride at week 48. In patients virologically suppressed with NVP-based regimens, RPV-based regimens can be a switch option.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- hiv infected patients
- hepatitis c virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- hiv positive
- prognostic factors
- peritoneal dialysis
- stem cells
- low density lipoprotein
- clinical trial
- randomized controlled trial
- patient reported outcomes
- cell therapy
- study protocol